| Literature DB >> 31701060 |
Swarnalata Gowrishankar1, Yashita Gupta1, Mahesha Vankalakunti2, Kiran K Gowda2, Anila A Kurien3, K S Jansi Prema3, N V Seethalekshmy4, Jyotsna Yesodharan4.
Abstract
Entities:
Year: 2019 PMID: 31701060 PMCID: PMC6829187 DOI: 10.1016/j.ekir.2019.06.013
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Figure 1Distribution of cases.
Figure 2Age distribution of cases.
Demographic, laboratory, and histologic data in the 4 centers and in the entire cohort
| Center | Bangalore | Chennai | Hyderabad | Kochi | Total |
|---|---|---|---|---|---|
| No. of IgAN cases | 1229 | 866 | 633 | 617 | 3345 |
| IgAN as a % of native biopsies | 14.2 | 12.5 | 10.4 | 17.1 | 13.23 |
| Mean age (yr) | 36.78 | 33.84 | 34.92 | 37.65 | 35.83 |
| Male:female ratio | 2.5:1 | 1.6:1 | 2.5:1 | 4.0:1 | 2.4:1 |
| Hypertension | 647/1103 | 445/828 | 373/532 | 397/617 | 1862/3080 |
| Proteinuria | |||||
| Semiquantitative (≥3+) | 625/1218 | 400/861 | 343/627 | 368/614 | 1736/3320 |
| Urine Pr:Cr ratio (≥1) | 393/420 | 253/318 | 64/78 | 134/150 | 844/966 |
| Urine Pr:Cr ratio (≥3) | 202/420 | 144/318 | 30/78 | 64/150 | 440/966 |
| 24 h proteinuria (≥3 gm/d) | 123/308 | 0 | 102/269 | 95/278 | 320/855 |
| Hematuria (≥2/hpf) | 720/961 | 568/661 | 422/528 | 385/469 | 2095/2619 |
| Mean serum creatinine | 3.9 | 2.8 | 3.3 | 3.1 | 3.27 |
| Histology-adequate biopsies | 426 | 416 | 242 | 361 | 1445 |
| M1 | 149 | 263 | 179 | 266 | 857 |
| E1 | 190 | 140 | 95 | 136 | 561 |
| S1 | 216 | 254 | 150 | 252 | 872 |
| T1 | 76 | 63 | 55 | 104 | 298 |
| T2 | 17 | 13 | 8 | 23 | 61 |
| C1 | 73 | 35 | 87 | 104 | 299 |
| C2 | 62 | 4 | 40 | 28 | 134 |
C, crescents; Cr, creatinine; E, endocapillary hypercellularity; IgAN, IgA nephropathy; M, mesangial hypercellularity; Pr, protein; S, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis.
The denominator indicates the total number in which the value of this variable was recorded.
MEST-C correlation with clinical variables
| Oxford scores | Serum creatinine (mg/dl); | Proteinuria (gm/d); | Hematuria (number/hpf); | |||
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | ||||
| M score 0 | 2.39 ± 5.03 | 0.776 | 3.57 ± 3.55 | 0.481 | 20.04 ± 22.5 | 0.8 |
| 1 | 2.45 ± 2.31 | 6.32 ± 9.69 | 21.08 ± 24.6 | |||
| E score 0 | 2.25 ± 3.94 | 6.40 ± 3.63 | 0.447 | 17.83 ± 19.87 | ||
| 1 | 2.71 ± 2.58 | 3.43 ± 2.85 | 25.82 ± 28.95 | |||
| S score 0 | 2.32 ± 2.42 | 0.366 | 3.49 ± 3.61 | 0.446 | 22.01 ± 22.18 | 0.510 |
| 1 | 2.50 ± 4.01 | 6.43 ± 4.35 | 20.4 ± 25.0 | |||
| T score 0 | 2.05 ± 3.66 | 3.29 ± 3.19 | 23.06 ± 26.25 | |||
| 1 | 3.07 ± 2.17 | 15.44 ± 10.31 | 23.06 ± 26.25 | |||
| 2 | 5.75 ± 3.39 | 4.59 ± 3.01 | 15.80 ± 18.27 | |||
| C score 0 | 2.14 ± 3.66 | 3.53 ± 3.64 | 0.215 | 17.98 ± 20.17 | ||
| 1 | 2.41 ± 2.33 | 11.50 ± 9.13 | 22.66 ± 22.60 | |||
| 2 | 4.69 ± 3.52 | 3.99 ± 3.09 | 30.22 ± 39.50 | |||
C, crescents; E, endocapillary hypercellularity; M, mesangial hypercellularity; S, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis.
The figures in bold indicate the correlations that were significant (P < 0.05).
Figure 3Immunofluorescence distribution.
IgA nephropathy studies in India
| Author | Year | No. | Mean age (yr) | Hypertension (%) | Proteinuria nephrotic range (%) | Hematuria (%) | High serum creatinine (%) |
|---|---|---|---|---|---|---|---|
| Bhuyan | 1992 | 83 | – | 39 | 24 | – | 34 |
| Muthukumar | 2002 | 98 | 25.7 | 9.2 | 25.6 | 5.1 | 13.5 |
| Chacko | 2005 | 478 | 32 | 58 | 55 | 16 | 60 |
| Chandrika | 2007 | 227 | 30 | 35 | 36.7 | 18.9 | 5.7 |
| Mittal | 2012 | 66 | 29.9 | 78.8 | 23.1 | 81 | – |
| Bhagchi | 2016 | 103 | 28.8 | 39.4 | 63.1 | 91 | 16.5 |
IgA nephropathy studies worldwide
| Author, country | Year | No. | Mean age (yr) | HTN (%) | Proteinuria | Hematuria (%) | High serum creatinine (%) |
|---|---|---|---|---|---|---|---|
| Nicolls | 1984 | 244 | 32 | 23 | 6 | 39 | 36 |
| D’Amico | 1986 | 365 | 29 | 36 | 7 | 55 | 24 |
| Droz | 1984 | 280 | – | 6 | 10 | 37 | – |
| Bogenschutz | 1990 | 239 | – | 19 | – | 26 | 34 |
| Rekola | 1990 | 209 | 25 | 11 | 1 | 64 | 16 |
| Alamartine | 1991 | 282 | 28 | 9 | 3 | 39 | 2 |
| Katafuchi, | 1994 | 225 | 32 | 22 | 16 | 20 | 36 |
| Koyoma | 1997 | 448 | – | 29 | 3 | 24 | 19 |
| Roberts | 2009 | 265 | 30 | 31 | 1.7 gms (mean) | 34 | 26 (CKD ≥3) |
| Zeng | 2011 | 1026 | 34 | 33 | 1.3 gms (mean) | 27 | 24 (CKD ≥3) |
| Katafuchi | 2011 | 702 | 30 | UPCR 0.9 (mean) | 25 (CKD ≥3) | ||
| VALIGA cohort | 2014 | 1147 | 36 | 65 | 21 | 37 (CKD ≥3) | |
| Present study | 2019 | 3345 | 35.8 | 60.4 | 37.4 | 79.9 (≥2/hpf) 3.9 (plenty) | 78.9 (≥1 mg/dl) |
CKD, chronic kidney disease; HTN, hypertension; UPCR, urine protein-to-creatinine ratio; VALIGA, Validation Study of the Oxford classification of IgAN.